Furthermore, improved perfusion has been reported in a subset of glioblastoma multiforme (GBM) patients treated with cediranib (a pan-VEGF TKI) or cediranib-containing regimens, and was associated with survival benefit (61, 65). This evidence concerns the gene VEGFA and glioblastoma.